Ivan Galanin Appointed to Head Commercial Development at Mount Sinai School of Medicine’s Office of Technology and Business Development
Mr. Galanin will be responsible for identifying industrial and investment partners.
Ivan Galanin, an experienced research and development strategist, has joined Mount Sinai School of Medicine as Director of Commercial Development in the Office of Technology and Business Development. His appointment will begin April 9, 2012.
Reporting to Teri Willey, Vice President for Technology and Business Development, Mr. Galanin will be responsible for identifying industrial and investment partners for the School’s growing intellectual property portfolio. Mr. Galanin will also be working with Dr. Scott Friedman, the recently appointed Dean of Therapeutic Discovery, on MSSM outreach to pharmaceutical and biotechnology companies.
"Mr. Galanin is the ideal person to assist our efforts in leveraging Mount Sinai’s know-how with the pharmaceutical industry," said Willey. "His seventeen year career in big pharma spans research and development strategy, commercial assessment, and deal making, including major collaborations with academia. We are delighted to have him as part of our team and the MSSM community."
Mr. Galanin was recruited to Mount Sinai from Sanofi, Inc., where as Director for Commercial Viability, he provided commercial guidance to the senior management of the Genzyme R&D Center, Sanofi’s main research hub in the United States. Prior to this position, Mr. Galanin was instrumental in shaping the strategic direction of the Fibrosis and Wound Repair R&D Unit, setup by Sanofi in 2009 to address a new set of unmet medical needs. He also planned and negotiated the first major academic research collaboration for Sanofi-Aventis, as well as initiated the company’s first innovative licensing deals. Within Sanofi-Aventis, Mr. Galanin concluded agreements accounting for more than $1 billion worth of assets changing hands.
Mr. Galanin has an undergraduate degree in German History from Yale University and a Master’s of Science in Corporate Finance from Carnegie Mellon University.
About The Office of Technology and Business Development
The Office of Technology and Business Development (OTBD), as part of The Mount Sinai School of Medicine (MSSM), facilitates the transfer of discovery from the laboratory to the marketplace, acting as the interface with commercial entities.
OTBD is responsible for the full spectrum of commercialization activities required to bring MSSM’s inventions to life. These activities include evaluating, patenting, marketing, and licensing new technologies, while also negotiating various agreements for sponsored research, material transfer, and confidentiality. Through Blue Mountain Technologies, OTBD also utilizes MSSM’s growing portfolio of molecular diagnostic reagents to assist partners with advancing research and commercialization.
Since its inception in 1991, the Office has played a significant role in alliance management to ensure MSSM and its partners are continuously meeting their goals. OTBD has managed industry relationships that have resulted in numerous products to address patient needs (including more than 15 technologies in preclinical or clinical development) and 11 companies based on MSSM technologies.
About The Mount Sinai Medical Center
The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Mount Sinai School of Medicine. Established in 1968, Mount Sinai School of Medicine is one of the leading medical schools in the United States. The Medical School is noted for innovation in education, biomedical research, clinical care delivery, and local and global community service. It has more than 3,400 faculty in 32 departments and 14 research institutes, and ranks among the top 20 medical schools both in National Institutes of Health (NIH) funding and by U.S. News & World Report.
The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation’s oldest, largest and most-respected voluntary hospitals. In 2011, U.S. News & World Report ranked The Mount Sinai Hospital 16th on its elite Honor Roll of the nation’s top hospitals based on reputation, safety, and other patient-care factors. Of the top 20 hospitals in the United States, Mount Sinai is one of 12 integrated academic medical centers whose medical school ranks among the top 20 in NIH funding and U.S. News & World Report and whose hospital is on the U.S. News & World Report Honor Roll. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 560,000 outpatient visits took place.
For more information, visit http://www.mountsinai.org/.